Instil Bio (TIL) Gets a Buy from Robert W. Baird

In a report released on January 9, Jack Allen from Robert W. Baird maintained a Buy rating on Instil Bio (TILResearch Report), with a price target of $5.00. The company’s shares closed yesterday at $0.73.

According to TipRanks, Allen is an analyst with an average return of -15.2% and a 42.86% success rate. Allen covers the Healthcare sector, focusing on stocks such as Instil Bio, Lineage Therap, and Frequency Therapeutics.

Instil Bio has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $14.34 and a one-year low of $0.47. Currently, Instil Bio has an average volume of 1.44M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Instil Bio Inc is a clinical-stage cell therapy company. It is developing tumor infiltrating lymphocytes for the treatment of cancer.

Read More on TIL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More